Rare Disease Biomarkers and Companion Diagnostics

Rare Disease Biomarkers and Companion Diagnostics

From identifying targets, influencing market access and supporting physician treatment decisions, biomarkers and companion diagnostics (CDx) are central to the success of the increasingly important rare disease sector.

So, what are the latest advances?

How are biomarkers enabling scientists to look beyond the molecule?

Can you create high-quality datasets from limited patient populations?

In what ways are biomarkers and CDx supporting market access?

How is AI changing the game?

For answers, turn to this detailed expert report, Rare Disease Biomarkers and Companion Diagnostics.

Companies

Roche, AstraZeneca, Daiichi Sankyo, Astellas, Amazon, Chiesi, Astex Pharmaceuticals, Takeda, WuXi, Insilico Medicine, Otsuka Pharmaceuticals, Microsoft, Exelixis, Ipsen, Ionis, Abbott Molecular, ARUP Laboratories, Centogene, Deep Genomics, Foundation Medicine, Molecular MD Corporation, Verge Genomics, Ad Scientiam